Oral Metformin/Oral Inhibitor Mouse Study - Imatinib CSV JSON

In Vivo Interaction Study

Oral Metformin/Oral Inhibitor Mouse Study - Imatinib

Decreased systemic exposure was detected.

metformin 1503297

imatinib

Results

Control:
-AUC0-4h: 4.7 (24)
-AUCR (ratio of AUC0-4h in presence of test article to vehicle; values represented as geometric means with 90% CI): N/A
-AUCR (ratio of AUC0-12h in presence of test article to vehicle; values represented as geometric means with 90% CI): N/A
Test:
-AUC0-4h: 3.7 (12)
-AUCR (ratio of AUC0-4h in presence of test article to vehicle; values represented as geometric means with 90% CI): 0.79 (0.65-0.96)
-AUCR (ratio of AUC0-12h in presence of test article to vehicle; values represented as geometric means with 90% CI): 0.89 (0.74-1.07)

Sample Compound measured Value Measurement Study sequence Additional information N replicates

Experimental Conditions

Blood was used for LC-MS analysis.

Single dosing

Population

Males

FVB

8 per test group

The form has been tweaked for the mice study. 
Study population: mice
Study population phenotype: Jackson laboratory (Bar Harbor, Maine)

Pharmacokinetic (PK) Sampling Information

0.25, 0.5, 1, 2, 4, 8, and 12 h

None

Drug or Natural Product Administration

Object Administration — metformin

Oral

Liquid

Metformin (10 mg/kg)

Single dose administered by oral gavage at 10 ml/kg for both goldenseal and other test articles.

Once

Precipitant Administration — imatinib

Oral

N/A

Imatinib (100 mg/kg)

Single dose administered by oral gavage at 10 ml/kg for both goldenseal and other test articles.

Once

Natural Product Characteristics

Goldenseal

Yes - sent to Clarke lab by Dr. Oberlies at UNCG

N/A

Pharmacodynamics (PD) & Adverse Events

N/A

N/A

N/A